56% of adults support easing federal embryonic stem cell research funding restrictions

About 56% of U.S. adults support easing restrictions on federal funding for human embryonic stem cell research, according to an Associated Press-AOL poll conducted from Dec. 19, 2006, to Dec. 21, 2006, the AP/Washington Post reports (Superville, AP/Washington Post, 1/3).

The poll also found that 43% opposed easing the restrictions (Associated Press/AOL Poll, 12/21/06).

Federal funding for embryonic stem cell research is allowed only for research using embryonic stem cell lines created on or before Aug. 9, 2001, under a policy announced by President Bush on that date.

Bush in July 2006 vetoed the Stem Cell Research Enhancement Act of 2005 (HR 810), which would have expanded stem cell lines that are eligible for federal funding and allowed funding for research using stem cells derived from embryos originally created for fertility treatments and willingly donated by patients.

Democratic congressional leaders this month plan to approve a bill similar to the Stem Cell Research Enhancement Act (Kaiser Daily Women's Health Policy Report, 11/30/06).

According to the AP/Post, supporters of embryonic stem cell research say it could lead to treatments for conditions such as Parkinson's disease and spinal cord injuries, while opponents of the research say human embryos should not be destroyed for research purposes.

The poll was conducted by Ipsos and has a margin of error of about three percentage points (AP/Washington Post, 1/3).

The poll is available online. Note: You must have Adobe Acrobat to view the survey.


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Obe-cel demonstrates strong efficacy and safety in treating leukemia